These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 15177844)
21. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
22. [Broad-spectrum beta-lactamases in Gram-negative bacteria]. Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Pfaller MA; Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951 [TBL] [Abstract][Full Text] [Related]
25. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Rhomberg PR; Jones RN Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243 [TBL] [Abstract][Full Text] [Related]
26. New strategies to identify patients harbouring antibiotic-resistant bacteria at hospital admission. Tacconelli E Clin Microbiol Infect; 2006 Feb; 12(2):102-9. PubMed ID: 16441446 [TBL] [Abstract][Full Text] [Related]
27. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. McGowan JE Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S29-37; discussion S64-73. PubMed ID: 16813979 [TBL] [Abstract][Full Text] [Related]
28. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Hawkey P; Finch R Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318 [TBL] [Abstract][Full Text] [Related]
29. Changing bacterial isolates and antibiotic sensitivities of purulent dacryocystitis. Briscoe D; Rubowitz A; Assia EI Orbit; 2005 Jun; 24(2):95-8. PubMed ID: 16191795 [TBL] [Abstract][Full Text] [Related]
30. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Garrison MW; Neumiller JJ; Setter SM Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603 [TBL] [Abstract][Full Text] [Related]
32. What's new in antibiotic resistance? Focus on beta-lactamases. Babic M; Hujer AM; Bonomo RA Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402 [TBL] [Abstract][Full Text] [Related]
33. Infectious diseases and antibiotic resistance in long-term care facilities. Bonomo RA Postgrad Med; 2001 Feb; 109(2 Suppl):70-7. PubMed ID: 19667560 [TBL] [Abstract][Full Text] [Related]
34. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Siegel RE Respir Care; 2008 Apr; 53(4):471-9. PubMed ID: 18364060 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of methicillin-resistant Staphylococcus aureus and factors associated with colonization among residents in community long-term-care facilities in Spain. Manzur A; Gavalda L; Ruiz de Gopegui E; Mariscal D; Dominguez MA; Perez JL; Segura F; Pujol M; Clin Microbiol Infect; 2008 Sep; 14(9):867-72. PubMed ID: 18844688 [TBL] [Abstract][Full Text] [Related]
36. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics]. Susić E Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687 [TBL] [Abstract][Full Text] [Related]
37. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C; Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645 [TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
39. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
40. What's new on the antimicrobial horizon? Song JH Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]